Examines annualized relapse rates in multiple sclerosis patients transitioning to two therapies, indicating potential treatment differences.
To estimate the annualized relapse rate (ARR) in patients with multiple sclerosis (PwMS) who switched from an anti-CD20 to fumarates (anti-CD20-FUM) vs those who switched from an anti-CD20 to cladribine (anti-CD20-CLAD).
No takes yet. Share an insight, caveat, or question.
Berkovich et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: